Pancreatic Cancer Early Detection Biomarkers for High-Risk Individuals: Insights From the PRECEDE Consortium.
Current biomarkers for early pancreatic cancer in high-risk families show promise but need prospective validation before clinical use in germline mutation carriers.
This review from the international PRECEDE Consortium synthesizes current evidence on biomarkers for early pancreatic cancer detection in high-risk germline mutation carriers (BRCA, PALB2, ATM), identifying CA19-9, ctDNA, and novel protein markers as most promising but not yet clinically ready as standalone tests. The consortium framework provides a roadmap for prospective validation studies in this vulnerable, high-mortality-risk population.
What the study was
- Study design
- Consortium review summarizing biomarker findings from the PRECEDE (Pancreatic Cancer Early Detection) Consortium for high-risk individuals (germline BRCA, PALB2, ATM, etc.)
- Population
- High-risk individuals (germline pancreatic cancer mutation carriers) under surveillance
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- International Journal of Cancer
Why it surfaced
Pancreatic cancer in high-risk germline carriers is a high-priority early detection need; PRECEDE is a major consortium. Review design limits score to 6.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.